// App-Quantinova.ai

POS0648 (2021) : SURVIVAL ANALYSIS OF TIME TO FIRST ADVERSE DRUG REACTION AND DRUG SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH METHOTREXATE AND HYDROXYCHLOROQUINE MONOTHERAPIES OR COMBINATION THERAPY

Researchers

Presenter

  • K. Velthuis

Principal Investigators

  • M. Nguyen

  • J. Jansen

  • J. Van Lint

  • P. Ten Klooster

  • H. Vonkeman

  • N. Jessurun

Medical Centers

  • Netherlands Pharmacovigilance Centre Lareb, Signal detection, ‘s-Hertogenbosch, Netherlands

  • Transparency in Healthcare B.V., Hengelo, Overijssel, Netherlands

  • University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands

  • Medisch Spectrum Twente, Arthritis Center Twente - Rheumatology and Clinical Immunology, Enschede, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Aldo-Keto Reductase Family 1 Member B

Drug/Treatment

  • Hydroxychloroquine

  • Methotrexate

Outcome

  • N/A

Study Design

  • Cohort

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved